For veterinary finished-dose manufacturers, the selection of a dry active pharmaceutical ingredient that can move across tablet compression, capsule filling, granulation, premix dilution, injectable compounding, and solution preparation without requiring a different chemical entity is governed by particle-size control, residual solvent status, microbial and endotoxin burden, and the documentary chain linking each lot to the active substance master file.

The product introduced here is designated Qihe Powder Veterinary Grade API. No public model code is supplied; the manufacturer differentiates lots by milling profile and target particle-size distribution on the certificate of analysis. The general compression grade is intended for direct compression, wet granulation, dry granulation, capsule filling, and premix manufacture. The micronized grade is intended where injectable suspension uniformity, rapid dissolution, or very low-dose solid-oral blending requires a fine to micronized particle population. Published data specific to this tradename are limited; the following parameters therefore reflect compendial and equipment-defined thresholds rather than a proprietary stability database.

The active substance is a white to off-white crystalline powder with drying loss controlled to the applicable monograph specification. For non-sterile solid dosage forms, the microbial quality target is 10³ CFU/g for total aerobic microbial count and 10² CFU/g for combined yeasts and moulds under Ph. Eur. 5.1.4; injectable grades are additionally evaluated for bacterial endotoxins by USP <85> or Ph. Eur. 2.6.14. The physical form is selected to balance flow and compressibility: a bulk density between 0.35 g/mL and 0.55 g/mL, an angle of repose below 35°, and a Hausner ratio below 1.35 are typical release targets for tablet and capsule lines, though the actual lot certificate controls the release decision.

How Does the Powder Meet Compendial Identity, Purity, and Residual Solvent Expectations?

Release testing is configured as a multi-method platform. Identity is confirmed by chromatographic retention against a reference standard and by infrared absorption according to the relevant monograph; assay on dried basis is typically controlled at 98.0–102.0% by high-performance liquid chromatography under USP <621> or equivalent Ph. Eur. methodology. Related substances and degradation products are limited by area normalisation; the specific thresholds are monograph-defined and are reported on each certificate of analysis.

Water content is measured by Karl Fischer titration according to USP <921> or Ph. Eur. 2.5.12; loss on drying is determined at 105°C by USP <731>. Residual solvents are screened by headspace gas chromatography under USP <467> with acceptance mapped to VICH GL18 and ICH Q3C classes. Elemental impurities are controlled under USP <232>/<233> or Ph. Eur. 2.4.20, with limits selected according to the intended route of administration and maximum daily dose.

Particle-size distribution is measured by laser diffraction under ISO 13320:2020 or analytical sieving under Ph. Eur. 2.9.38. The general grade is typically released with a D50 in the 75–150 µm range for tablet and granule lines; the micronized grade is controlled to a D50 below 15 µm and a D90 below 35 µm for injectable suspension or low-dose blending. These values are representative of common milling targets rather than product-specific stability claims.

Because the powder is frequently introduced into direct compression and roller compaction lines, dry-state particle behaviour becomes a release and handling variable rather than a simple chemical test. On production-scale tablet presses, excessive fines can produce capping and lamination; overly coarse material can produce content uniformity failure at low dose. Therefore the milling step is usually followed by a de-lumping sieve and, where the process atmosphere exceeds 60% RH, a pre-conditioning step in a fluidized-bed or tray drier may be required to prevent water uptake during transfer.

For wet granulation in high-shear mixers, the powder is first dry-mixed with diluents and binders; the granulation endpoint is determined by impeller power consumption and torque rather than time alone. The API lot should have a reproducible particle-size span to avoid granule over-wetting. On a high-shear granulator of 600 L working capacity, pre-mix time of 3–5 min and main granulation time of 2–4 min are often used as starting conditions, but the endpoint is product-specific and must be established during process qualification.

Dry granulation by roll compaction is an alternative when the active substance is moisture-sensitive. The resulting ribbons are milled and screened through a 0.8–1.25 mm screen to produce granules with reduced dusting; however, the compression step may reduce tablet hardness relative to direct compression unless the formulation includes a brittle filler. Published data for this specific configuration are limited and process validation is required.

When Tablet, Capsule, and Granule Lines Require Flow-Active, Low-Fines Feedstock

Transfer of the general milling grade into tablet compression begins with a pre-blend in a bin blender or V-blender. The powder is blended with microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and magnesium stearate; lubricant addition is delayed to 3–5 min before compression to reduce the risk of over-lubrication. The pre-lubricated blend is sampled at 10 locations in a 600 L bin blender and tested for blend uniformity using a limit of ±5% relative standard deviation or per the approved sampling protocol. The compression target is set by USP <905> content uniformity at 85–115% of label claim for first-stage testing; USP <701> disintegration and USP <711> dissolution are used to link tablet hardness and disintegration time.

Capsule filling on an automatic dosator or tamping-pin machine uses the same pre-blend or a dry granulation. The fill weight is controlled gravimetrically at ±5% of the target fill mass, and the powder bed depth is maintained so that bulk density stays within the validated range. A Hausner ratio below 1.35 and an angle of repose below 35° reduce die fill variation. Where capsule shells are hard gelatin, water activity below 0.6 aw is usually confirmed to avoid brittle shells; hypromellose capsules may be selected when crosslinking is a risk.

Granules for sachets and oral powders are produced by wet granulation or dry compaction and then sieved. The final granule fraction is often controlled to 150–850 µm, with fines passing a 150 µm sieve kept below 20% to limit segregation during packaging. The loss on drying of the finished granule is brought to ≤2.0% before filling into aluminium-polyethylene peelable sachets, unless the product is moisture-bearing by design.

The compression sequence may also include a pre-compression force of 2–4 kN followed by main compression of 8–18 kN on rotary presses fitted with 10 mm flat-faced or biplanar punches; these conditions are equipment-specific and are not universal. Tablet hardness is typically monitored at 60–120 N for standard tablets, while friability is kept below 1.0% according to USP <1216> or Ph. Eur. 2.9.7. If hardness falls below 50 N, the lot is not released without a deviation investigation.

Injectable Solution and Suspension Processing Boundaries

A solution-based injectable formulation starts with water for injection in a 316L stainless steel mixing vessel. The API is charged under low-shear agitation; if the pH is outside the stable range, the solution may require pre-dissolution adjustment with dilute hydrochloric acid or sodium hydroxide. The solution is filtered through a 0.45 µm pre-filter and then a 0.22 µm sterilising-grade membrane; the exact filter area is chosen to keep the volume throughput below the validated flow rate per unit area. The use of a micronized injectable-grade API reduces the load on the sterilising filter and shortens the dissolution time, but the resulting solution must meet USP <788> particulate matter limits and the applicable clarity specification.

For suspension-based injectables, particle-size distribution is critical because large crystals can settle and cause syringeability failure. The micronized grade is typically wet-milled in a high-shear rotor-stator or bead mill to a D90 below 35 µm; the suspension is then filled under continuous agitation through a piston-pump line. The injection is tested for syringeability using a 21-gauge needle and for sedimentation volume after 24 h. Bacterial endotoxin control is maintained at ≤0.25 EU/mg or tighter if the maximum daily dose demands it; the limit is calculated according to the maximum bolus dose and the route of administration.

Terminal sterilisation by autoclaving may be applied only when stability-indicating assay and impurity testing show no degradation under the selected cycle. Where the API is heat-sensitive, aseptic processing is used instead. Published data specific to Qihe Powder are limited; therefore, sterilisation cycle selection must be verified on a lot-specific basis using thermal stability studies in the finished container.

For injectable solutions, dissolved oxygen in the mixing vessel is sometimes reduced by nitrogen sparging before API addition. If the active substance contains a readily oxidisable functional group, the solution is protected from light and the headspace is flushed with nitrogen during filling. The dose is filled through a peristaltic or piston-pump filling line; filling accuracy is typically controlled to ±2% of the target volume. After filling, the containers are subjected to 100% visual inspection and tested for container–closure integrity according to USP <1207> or equivalent. Published data for this specific API configuration are limited; the fill-and-finish validation must therefore include spiked degradation challenge studies rather than relying solely on historical production data.

For premix and feed-mediated applications, the powder is blended into a mineral or lactose carrier at a final concentration that may range from 0.1% to 5% active substance, depending on the target species and daily feed intake. A horizontal ribbon blender or drum mixer is typically used; the active is first mixed with a portion of carrier at a 1:5 to 1:10 ratio before being added to the full batch. The blend is sampled at 10 locations and tested for assay and homogeneity; the target relative standard deviation is traditionally below 5%. Dusting is controlled by selecting a general milling grade with low fine-particle content and by adding a non-solvent binder in granulated premix formulations.

Solution-based oral or injectable preparations differ from solid premixes in that dissolution rate, clarity, and pH are controlling. The powder is reconstituted in purified water or water for injection at a defined concentration; if the solution is intended for drinking water medication, the solution must be freely soluble in water at the use concentration and stable for 24–48 h under field conditions. Data for this specific field-use claim are limited; stability-in-use should be confirmed in the intended water quality because alkalinity and chlorination can influence degradation.

Compared with a feed-grade or technical-grade powder, the veterinary-grade API carries a compendial release specification and is supplied with batch records that allow the finished-product manufacturer to avoid re-qualifying the chemical entity from first principles. The main operational differences are not necessarily chemical but documentary and physical: the lots have controlled fines, declared residual solvents, microbial limits, and an endotoxin statement for injectable use.

Premix and feed-delivered dose forms demand measurable differences in release controls

The primary differentiation between Qihe Powder Veterinary Grade API and less-regulated powders is the release and documentation package. The powder is produced under GMP for active substances according to EU GMP Part II and supported by batch certificates that state the actual assay, water content, particle-size distribution, microbial status, and residual solvent profile. This allows a single API to be evaluated for solid oral, feed, and sterile liquid routes without first re-testing the entire compendial monograph from first principles.

For human-grade API, the chemistry may be identical, but the veterinary drug submission may require residue, target animal safety, and environmental exposure packages under VICH; the use of a human-grade active in a veterinary finished product is not a simple substitution because the regulatory file, impurity thresholds, and excipient compatibility may differ. Similarly, a feed-grade powder may comply with feed hygiene but not with pharmacopoeial monograph identity and purity tests; use in injectable or tablet products without additional purification and documentation is outside GMP boundaries.

The Qihe Powder is therefore positioned as a single veterinary-grade API with multiple milling profiles rather than as an automatic replacement for all human or feed applications; each dosage-form project should be supported by a process equivalence study, a stability-indicating method, and a batch-to-batch particle-size trend analysis.